Browse ACKR3

Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Cytoplasm, perinuclear region. Early endosome. Recycling endosome Note=Predominantly localizes to endocytic vesicles, and upon stimulation by the ligand is internalized via clathrin-coated pits in a beta-arrestin-dependent manner. Once internalized, the ligand dissociates from the receptor, and is targeted to degradation while the receptor is recycled back to the cell membrane.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Atypical chemokine receptor that controls chemokine levels and localization via high-affinity chemokine binding that is uncoupled from classic ligand-driven signal transduction cascades, resulting instead in chemokine sequestration, degradation, or transcytosis. Also known as interceptor (internalizing receptor) or chemokine-scavenging receptor or chemokine decoy receptor. Acts as a receptor for chemokines CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization and activation of MAPK signaling pathway. Required for regulation of CXCR4 protein levels in migrating interneurons, thereby adapting their chemokine responsiveness. In glioma cells, transduces signals via MEK/ERK pathway, mediating resistance to apoptosis. Promotes cell growth and survival. Not involved in cell migration, adhesion or proliferation of normal hematopoietic progenitors but activated by CXCL11 in malignant hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1) and enhanced cell adhesion and migration. Plays a regulatory role in CXCR4-mediated activation of cell surface integrins by CXCL12. Required for heart valve development. Acts as coreceptor with CXCR4 for a restricted number of HIV isolates.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0006898 receptor-mediated endocytosis
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0031623 receptor internalization
GO:0043112 receptor metabolic process
GO:0043410 positive regulation of MAPK cascade
GO:0048514 blood vessel morphogenesis
GO:0070098 chemokine-mediated signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0097193 intrinsic apoptotic signaling pathway
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902532 negative regulation of intracellular signal transduction
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0001637 G-protein coupled chemoattractant receptor activity
GO:0001653 peptide receptor activity
GO:0004896 cytokine receptor activity
GO:0004950 chemokine receptor activity
GO:0005044 scavenger receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0015026 coreceptor activity
GO:0016494 C-X-C chemokine receptor activity
GO:0019955 cytokine binding
GO:0019956 chemokine binding
GO:0019958 C-X-C chemokine binding
GO:0038024 cargo receptor activity
Cellular Component GO:0005769 early endosome
GO:0005905 clathrin-coated pit
GO:0055037 recycling endosome
GO:0098589 membrane region
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ACKR3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ACKR3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ACKR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.930.0385
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8030.585
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0050.246
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6030.227
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5980.735
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6110.777
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0060.991
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0120.991
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1380.917
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2390.872
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.570.449
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2230.225
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ACKR3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACKR3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACKR3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACKR3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACKR3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ACKR3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ACKR3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolACKR3
Nameatypical chemokine receptor 3
Aliases GPR159; CMKOR1; CXCR7; chemokine orphan receptor 1; chemokine (C-X-C motif) receptor 7; CXC-R7; CXCR-7; C-X- ......
Chromosomal Location2q37.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ACKR3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.